Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Aggressive statins may halt artery clogging in young hearts

NCT ID NCT06896708

Disease control Sponsor: Liu yong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This nationwide trial tests whether intensive cholesterol-lowering drugs (statins plus ezetimibe or PCSK9 inhibitors) can slow plaque buildup in heart arteries better than standard statin therapy. About 766 adults aged 18–60 with chronic coronary syndrome and moderate artery blockages will be randomly assigned to one of two treatment strategies. The goal is to see if driving LDL cholesterol below 1.0 mmol/L prevents plaque progression and reduces heart attacks or hospitalizations.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Intensive lipid-lowering therapy (atorvastatin or rosuvastatin plus ezetimibe or PCSK9 inhibitor)
What this could lead to
If successful, this could show that aggressive cholesterol lowering slows or stops artery plaque progression, reducing heart attack risk in younger patients.
What could go wrong
This is an open-label trial (no placebo), so results may be biased. The intensive regimen may cause more side effects like muscle pain or liver issues, and long-term benefits are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 766 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1\. Aged 18-60 years at screening 2. Stable angina symptoms with suspected or confirmed coronary artery disease; 2. CCTA examination demonstrating: at least one major coronary artery with a diameter of ≥1.5mm that has not been intervened and at least one leision with 50%-70% stenosis. 3\. Subjects who have been using statin therapy alone for at least 4 weeks prior to enrollment with a baseline LDL-C ≥1.8mmol/L or subjects who have not initiated lipid-lowering therapy prior to enrollment with a baseline LDL-C≥2.6mmol/L. Exclusion Criteria: 1. Left main coronary artery disease or severe three-vessel disease; 2. Ultra-high-risk ASCVD patients: ≥2 severe ASCVD events or 1 severe ASCVD event with ≥2 high-risk factors; 3. Use of PCSK9 inhibitors or ezetimibe within 8 weeks prior to study enrollment; 4. The baseline LDL-C was relatively high (LDL-C≥2.6 mmol/L in those taking statins and ≥4.9 mmol/L in those not taking statins). 5. Familial hypercholesterolemia; 6. Known allergy/intolerance to lipid-lowering drugs used in the trial; 7. Patients with severe congestive heart failure, liver or kidney dysfunction, or malignancy; 8. Pregnant or breastfeeding female patients.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic coronary syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic coronary syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Guangdong Provincial People's Hospital

    RECRUITING

    Guangzhou, Guangdong, 510100, China

  • The Eighth Affiliated Hospital of Sun Yat-sen University

    NOT_YET_RECRUITING

    Shenzhen, Guangdong, 518033, China

  • The First Affiliated Hospital of Chongqing Medical University

    NOT_YET_RECRUITING

    Chongqing, Chongqing Municipality, 400015, China

  • The First Affiliated Hospital of Dalian Medical University

    NOT_YET_RECRUITING

    Dalian, Liaoning, 116000, China

  • The Ninth Clinical Medical College of Guangzhou University of Chinese Medicine

    NOT_YET_RECRUITING

    Dongguan, Guangdong, 523000, China

  • The Third Affiliated Hospital of Guangzhou Medical University

    NOT_YET_RECRUITING

    Guangzhou, Guangdong, 510000, China

  • Zhongshan People's Hospital

    NOT_YET_RECRUITING

    Zhongshan, Guangdong, 528400, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.